Pre-clinical study done at Science-in-Action, Israel; Blood analyses performed at the Hebrew University of Jerusalem, Israel
Why is bioavailability important?
DOC-CBD was created to solve the fundamental issues associated with conventional CBD products; low bioavailability, short shelf life, and the wide array of false claims regarding nanotechnology and effectiveness.
Notice that ordinary CBD products in orange have very minimal absorption into the bloodstream at 0.5 hours and 2.0 hours compared to DOC-CBD absorption in green has a significant increase absorption at both intervals.
Notice that the ordinary CBD products in orange deteriorate rapidly, whereas the horizontal green line shows that DOC-CBD maintains its integrity in the presence of stomach acid.
Fares Better in the Stomach
DOC-CBD’s patented technology, nextCBD™, retains integrity in the stomach, allowing more of the active ingredient to absorb into the bloodstream. Ordinary CBD products breakdown quickly, and deteriorate into other substances, resulting in a reduced effect.
DOC-CBD’s products are more effective at treating symptoms caused by inflammation due to the increased bioavailability. The same amount of ingredients translates into a better treatment experience.
TNF is one of many cytokine inflammation markers.
Notice that in preclinical trials ordinary CBD products in orange do not reduce the inflammatory marker TNF, compared to the significant drops in TNF levels after the administration of DOC-CBD labeled in green.
We believe that the poor performance of conventional administration of oral CBD is a result of poor bioavailability.
1. Mechoulam R., Parker L. A., Gallily R. (2002). Cannabidiol: an overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11S−19S. 10.1002/j.1552-4604.2002.tb05998.x
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
The statements made herein have not been evaluated by the US Food and Drug Administration and are not intended for diagnosing, treating, curing or preventing any disease or medical condition.